Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- IceCure Medical Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT02399124
- Locations
- 🇮🇱
Bnei Zion Medical Center, Haifa, Israel
🇮🇱Shamir Medical Center, Zerifin, Israel
Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
- Conditions
- Breast Cancer
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- IceCure Medical Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT02200705
- Locations
- 🇺🇸
Ironwood Cancer & Research Centers, Glendale, Arizona, United States
🇺🇸BreastLink, Santa Ana, California, United States
🇺🇸Bridgeport Hospital, Yale Medical School, Trumbull, Connecticut, United States
Laparoscopic Cryoablation of Uterine Fibroids
- Conditions
- Symptomatic Uterine Fibroids
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- IceCure Medical Ltd.
- Registration Number
- NCT01735812
- Locations
- 🇮🇱
Assaf Harofe, Zrifin, Israel
Cryotherapy for Breast Cancer Trial
- Conditions
- Breast Carcinoma
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- IceCure Medical Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT01671943
- Locations
- 🇨🇿
Oncogynecological Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague Prague, Czech Republic, Prague, Czech Republic
ICE-SENSE™ Cryotherapy for Breast Fibroadenoma Trial
- Conditions
- Fibroadenoma
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- IceCure Medical Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT00910312
- Locations
- 🇨🇿
Oncogynecological Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czechia
🇩🇪Department of Obstetrics and Gynecology, University Hospital of Heidelberg, Heidelberg, Germany
🇩🇪Department of Obstetrics and Gynecology, University Hospital of Tuebingen, Tübingen, Germany
News
ProSense® Cryoablation Shows Promise as Non-Surgical Alternative for Early-Stage Breast Cancer
Multiple studies presented at major European oncology conferences demonstrate ProSense® cryoablation system's effectiveness with 94% complete ablation rate in early-stage breast cancer patients.
IceCure Seeks NMPA Approval for Advanced ProSense Cryoablation System in China
IceCure Medical has submitted a regulatory application to China's NMPA for its ProSense cryoablation system, building upon their existing IceSense3 platform already approved in the market.
IceCure Medical Sees Sales Surge and Awaits FDA Decision on ProSense for Breast Cancer
IceCure Medical reported a 42% increase in North American sales of its ProSense cryoablation system in 2024, signaling growing adoption for breast tumor treatment.
IceCure Medical's ProSense Receives Favorable FDA Panel Recommendation
IceCure Medical's ProSense system received a favorable recommendation from the FDA Medical Device Advisory Committee for treating early-stage, low-risk breast cancer.
FDA Panel Backs IceCure's ProSense for Early-Stage Breast Cancer
An FDA advisory panel has favorably recommended IceCure Medical's ProSense cryoablation system for treating early-stage, low-risk breast cancer.
FDA Advisory Panel to Review IceCure's ProSense for Early-Stage Breast Cancer
The FDA's Medical Device Advisory Committee will review IceCure's ProSense cryoablation system for early-stage, low-risk breast cancer on November 7, 2024.
FDA Advisory Panel to Review IceCure's ProSense for Early-Stage Breast Cancer
The FDA's Medical Device Advisory Committee Panel will convene on November 7, 2024, to assess ProSense cryoablation for early-stage, low-risk breast cancer.